186 related articles for article (PubMed ID: 38255255)
1. Clinicopathological and Molecular Characteristics of
Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
4. Extra-CNS and dural metastases in
Kleinschmidt-DeMasters BK; Gilani A
Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017
[TBL] [Abstract][Full Text] [Related]
5. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors.
Guo X; Gu L; Li Y; Zheng Z; Chen W; Wang Y; Wang Y; Xing H; Shi Y; Liu D; Yang T; Xia Y; Li J; Wu J; Zhang K; Liang T; Wang H; Liu Q; Jin S; Qu T; Guo S; Li H; Wang Y; Ma W
Front Oncol; 2023; 13():1200815. PubMed ID: 37483487
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.
Lee B; Hwang S; Bae H; Choi KH; Suh YL
Brain Pathol; 2024 Jan; ():e13234. PubMed ID: 38217295
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma,
Broggi G; Piombino E; Altieri R; Romano C; Certo F; Barbagallo GMV; Vigneri P; Condorelli D; Colarossi L; Colarossi C; Magro G; Tirrò E
Front Neurol; 2022; 13():823015. PubMed ID: 35222252
[TBL] [Abstract][Full Text] [Related]
8. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
9. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
Di Stefano AL; Picca A; Saragoussi E; Bielle F; Ducray F; Villa C; Eoli M; Paterra R; Bellu L; Mathon B; Capelle L; Bourg V; Gloaguen A; Philippe C; Frouin V; Schmitt Y; Lerond J; Leclerc J; Lasorella A; Iavarone A; Mokhtari K; Savatovsky J; Alentorn A; Sanson M;
Neuro Oncol; 2020 Nov; 22(11):1614-1624. PubMed ID: 32413119
[TBL] [Abstract][Full Text] [Related]
10. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
[TBL] [Abstract][Full Text] [Related]
11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
12. Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas.
Hong L; Shi ZF; Li KK; Wang WW; Yang RR; Kwan JS; Chen H; Li FC; Liu XZ; Chan DT; Li WC; Zhang ZY; Mao Y; Ng HK
Lab Invest; 2022 Jul; 102(7):731-740. PubMed ID: 35332262
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract][Full Text] [Related]
14. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
15. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
16. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract][Full Text] [Related]
17. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.
Kumari K; Dandapath I; Singh J; Rai HIS; Kaur K; Jha P; Malik N; Chosdol K; Mallick S; Garg A; Suri A; Sharma MC; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):410-417. PubMed ID: 35708480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
